Aclaris Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Aclaris Therapeutics

19/02/2024 14:06

* Aclaris Therapeutics Inc  ACRS.OQ   ACRS.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
21 (estimated) for the period ending December 31 2023
    * The Wayne Pennsylvania-based  company is expected to
report a
56.6% decrease in revenue to $3.363 million from $7.75 million a
year ago, according to the mean estimate from 8 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Aclaris Therapeutics Inc
is
for a loss of 34 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 8
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aclaris
Therapeutics Inc is $2.00​, above​ its last closing price
of $1.19. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.47       -0.48      -0.41     Beat    14.6
 Jun. 30 2023  -0.44       -0.45      -0.42     Beat    6.7
 Mar. 31 2023  -0.43       -0.44      -0.40     Beat    8.6​
 Dec. 31 2022  -0.45       -0.45      -0.41     Beat    8
 ​​Sep.        -0.39       -0.40      -0.30     Beat    24.2
 30 2022                                                
 Jun. 30 2022  -0.36       -0.36      -0.31     Beat    13.5​
 Mar. 31 2022  -0.40       -0.40      -0.31     Beat    23.1
 Dec. 31 2021  -0.37       -0.36      -0.37     Missed  -1.4
 This summary was machine generated February 19 at 14:05 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)